Dr. Sima Ehsani Chimeh, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 235
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WI license 54738-20 -
Gynecologic Oncology Physician
WI license 54738
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Banner - University Medical Center Tucson Campus Tucson, AZ
- Banner-University Medical Center South Campus Tucson, AZ
Medical groups
- Banner-University Medical Group (1,072 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 235
- Services billed
- 545
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 215 | 125 |
| Established patient office or other outpatient visit, 40-54 minutes | 174 | 75 |
| New patient office or other outpatient visit, 60-74 minutes | 38 | 38 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Madison, WI | 350 |
| Letrozole Other prescribers in Madison, WI | 194 |
| Ibrance (palbociclib) | 67 |
| Exemestane | 63 |
| Tamoxifen Citrate Other prescribers in Madison, WI | 56 |
| Ibandronate Sodium Other prescribers in Madison, WI | 42 |
| Estradiol Other prescribers in Madison, WI | 38 |
| Dexamethasone Other prescribers in Madison, WI | 31 |
| Prochlorperazine Maleate Other prescribers in Madison, WI | 27 |
| Verzenio (abemaciclib) | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 8 payments worth $407 in total to this clinician.
| Stemline Therapeutics Inc. | $239 |
|---|---|
| Novartis Pharmaceuticals Corporation | $62.39 |
| AstraZeneca Pharmaceuticals LP | $54.13 |
| Gilead Sciences, Inc. | $30.95 |
| Springworks Therapeutics, Inc. | $20.52 |
| Food and Beverage | $407 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $157,767 in research payments for these studies, mostly to the institutions running them.
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals Inc. - A randomized phase ii trial of circulating tumor dnaguided second line adjuvant therapy for high residual risk estrogen receptor positive HER2 negative breast cancer DAREWI251141
Pfizer Inc. - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.